logo-loader
Arix Bioscience PLC

Artios in strong position to accelerate cancer programmes after Arix investment

Proactive Investors' Andrew Scott sits down with Arix Bioscience Plc's (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma.

Arix has recently upped its stake in Artios following a Series B financing round that was backed by the venture capital arms of industry giants Pfizer and Novartis.

Artios Pharma's developing DNA damage response technology to treat cancer.

Quick facts: Arix Bioscience PLC

Price: £1.16

Market: LSE
Market Cap: £156.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read